×

CytoDyn Announces Investment Community Conference Call

VANCOUVER, Wash., Nov. 18, 2015 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency virus (HIV), today announced that the Company will host a live conference call and webcast with the investment community on Friday, November 20, 2015 at 9:00 a.m. PT / 12 noon ET to provide an update on the Company's progress with PRO 140, its lead product candidate.

Conference Call and Webcast Instructions

CytoDyn's management team will host a conference call and live audio webcast on Friday, November 20, 2015 at 9:00 a.m. PT / 12 noon ET.

Interested participants and investors may access this conference call by dialing 877-407-2986 (U.S./Canada) or 201-378-4916 (international).

A live audio webcast may also be accessed via CytoDyn's corporate web site at http://cytodyn.equisolvewebcast.com/11-20-15 and will be archived for 30 days. Web participants are encouraged to go to the web site 15 minutes prior to the start of the call to register, download and install any necessary software.

A replay of the conference call will be available until December 1, 2015. To access the replay, interested parties may dial 877-660-6853 (U.S./Canada) or 201-612-7415 (International); Conference ID: 13578723.

About CytoDyn

CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has finished Phase 2 clinical trials with demonstrated antiviral activity in man and is currently in Phase 3. PRO 140 blocks the HIV co-receptor CCR5 on T-cells which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from six Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several months of interruption from conventional drug therapy. CytoDyn intends to continue to develop PRO 140 as a therapeutic anti-viral agent in persons infected with HIV. In addition, as a result of recent research of PRO 140's mechanism of action, the Company believes that PRO 140 may be effective in modulating some immune functions and therefore be effective in certain immunologic disorders. Based on these findings, the Company filed in October 2015 an investigational new drug application, or IND, and a full protocol with the FDA for a transplantation indication called graft-versus-host disease or GvHD, in patients undergoing bone marrow transplantation for acute myeloid leukemia, or AML, and myelodysplastic syndromes, or MDS. For more information on the Company, please visit www.cytodyn.com.

About PRO 140

PRO 140 belongs to a new class of HIV/AIDS therapeutics -- viral-entry inhibitors -- that are intended to protect healthy cells from viral infection. PRO 140 is a fully humanized IgG4 monoclonal antibody directed against CCR5, a molecular portal that HIV uses to enter T-cells. PRO 140 blocks the predominant HIV (R5) subtype entry into T-cells by masking this required co-receptor, CCR5. Importantly, PRO 140 does not appear to interfere with the normal function of CCR5 in mediating immune responses. PRO 140 does not have agonist activity towards CCR5 but does have antagonist activity to CCL5 which is a central mediator in inflammatory diseases. PRO 140 has been the subject of seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test subjects. PRO 140 has been designated a "fast track" product candidate by the FDA. The PRO 140 antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements as compared to daily drug therapies currently in use.

CONTACT: Investor Relations: Wolfe Axelrod Weinberger Associates, LLC Contact: Robert Schatz, Managing Director Office: 212-370-4500 E-mail: Rob@wolfeaxelrod.com Media: Dr. Nader Pourhassan Office: 360-980-8524 E-mail: npourhassan@cytodyn.com

Source:CytoDyn